Urovalve, Inc. to Present at Medtech Insight's ``Investment In Innovation'' Boston Conference.BOSTON -- Urovalve, Inc. has announced that it will be presenting at 2:50 PM on October 10, 2005 at Medtech Insight's "Investment In Innovation (In3) BOSTON: A Preview of Early-Stage Medical Technology Companies" Conference, taking place October 10-11, 2005 at The Westin Copley Place Copley Place is an enclosed shopping mall located in the Back Bay section of Boston, Massachusetts. It is part of a complex that includes office buildings, two hotels, and a parking garage. Hotel in Boston, MA. Urovalve's core technology is based on using patented magnetic fluid flow control valves. The Company's lead device, Surinate(TM) applies this technology to help men who suffer from urinary retention Urinary retention The result of progressive obstruction of the urethra by an enlarging prostate, causing urine to remain in the bladder even after urination. . A successful clinical feasibility study that was recently completed on the company's innovative valve controlled catheter demonstrated the potential of its simple, user-operated design. The Surinate(TM) intraurethral catheter uses a patented magnetic valve incorporated in a unique device that can be inserted into the urethra urethra (y  rē`thrə), canal in most mammals that carries urine from the bladder to the outside of the body; in the male it also serves as a genital duct. without surgery, extracted easily, and replaced every 28 days. Urination urinationProcess of excreting urine from the bladder (see urinary system). Nerve centres in the spinal cord, brain stem, and cerebral cortex control it through involuntary and voluntary muscles. The need to void is felt when the bladder holds 3. occurs when the user holds a simple hand held magnet nearby to open the valve. The Surinate(TM) catheter frees users from reliance on conventional catheters with leg-attached drainage bags or other care-giver dependent catheters. The design and simplicity of the device greatly improve patient quality of life and decrease the high incidence of urinary tract infections urinary tract infection (UTI), n infection in one or more of the structures that make up the urinary system. Occurs more often in women and is most commonly caused by bacteria. (UTI UTI urinary tract infection. UTI abbr. urinary tract infection UTI urinary tract infection. UTI Urinary tract infection, see there ) experienced with conventional catheters. Catheter-associated UTIs affect approximately 840,000 U. S. patients annually in acute care facilities and cost approximately $1,300 each to test and treat, resulting in nearly $2 billion wasted healthcare costs. Two high-tech alternatives are very expensive, virtually irreversible and require electronic controls. No devices currently available or known to be in development combine the utility, ease of use, and cost benefits of the Surinate(TM) catheter. The Company currently is planning the pivotal clinical study and is negotiating contract relationships for manufacturing and local distribution to demonstrate commercial viability. Broad distribution will be achieved through license arrangements or strategic partnerships Medtech Insight, a division of Windhover wind·hov·er n. Chiefly British A kestrel. Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation Boston" conference or for more information on Medtech Insight, please call Kristy Grimes at (480) 985-9512, e-mail kristy@medtechinsight.com, or visit www.medtechinsight.com. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion